Market News & Trends
Inovio Closes License & Collaboration Agreement With ApolloBio
Inovio Pharmaceuticals, Inc. recently announced it has closed an agreement providing ApolloBio Corp. with the exclusive right to develop, manufacture, and commercialize VGX-3100, Inovio’s DNA…
ERT Launches Phase I Site Certification Program to Improve Efficiencies in Clinical Development
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, recently announced it has launched a certification program for Phase…
Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV Versus NEPA Oral
Helsinn recently announced that the first patient has been enrolled in a Phase 3b study to assess the safety and tolerability of IV NEPA fixed…
Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial
Sienna Biopharmaceuticals, Inc. recently announced that the first patient has been dosed in the company’s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125…
DuPont’s Microbiome Venture Announces Second Strategic Partnership
Three months after its formation, the DuPont Nutrition & Health Microbiome Venture recently announced its second strategic research and development partnership. The newly forged relationship…
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product With Hitachi Chemical
SanBio Group and Hitachi Chemical Co., Ltd. jointly announced that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LCC, they will manufacture SB623, a…
Newly Issued US Patent Covers Spotlight Innovation's Spinal Muscular Atrophy Drug Candidates
Spotlight Innovation Inc. recently announced that US Patent No. 9,895,358, titled Combination Therapies for Treatment of Spinal Muscular Atrophy, has been issued to Indiana University…
Dalton Announces a Drug Development & GMP Manufacturing Services Agreement With Oryn Therapeutics
Dalton Pharma Services has recently announced the signing of a drug development and manufacturing services agreement with Oryn Therapeutics, an American biotechnology firm committed to…
Gerresheimer Unveils Innovative Vials Made From Glass & Plastic
Gerresheimer’s booth at the PDA Annual Meeting – held at the Loews Sapphire Falls Resort in Orlando from March 19 to 21 – was to…
Enteris BioPharma Initiates Feasibility Program With Ferring Pharmaceuticals to Develop Oral Formulation of a Peptide
Enteris BioPharma, Inc. recently announced it has entered into a feasibility development agreement with Ferring Pharmaceuticals to utilize Enteris' proprietary oral delivery platform, Peptelligence, to…
International Stem Cell Corporation Completes Dosing of Second Cohort in Parkinson's Disease Trial
International Stem Cell Corporation recently announced the eighth participant, which completes the dosing of the second cohort of the clinical trial for Parkinson's disease, was…
Ginolis Provides Mobidiag High Throughput Manufacturing Lines for Growing Needs of Novodiag Cartridges
Ginolis Ltd recently announced it has signed an agreement with Mobidiag Ltd, a Finnish molecular diagnostics for infectious diseases company. Through the implementation of cutting-edge…
Grand River Aseptic Manufacturing Continues to Expand Capabilities With New, State-of-the-Art Colanar Syringe Filler
Grand River Aseptic Manufacturing, Inc. (GRAM), a leading parenteral contract manufacturing organization, expands its capabilities in syringe filling at its FDA-inspected, cGMP-compliant manufacturing facility in…
SELLAS Life Sciences Group Announces Notice of Allowance From US PTO for New Patent Covering Composition of Matter for WT-1 Peptides
SELLAS Life Sciences Group, Inc. recently announced that the US PTO issued a Notice of Allowance for US Patent Application No. 14/760,997 related to certain Wilms Tumor 1 (WT1) peptides.
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be the first of several anticipated IND submissions in 2018 utilizing JOT’s platform product,JOTROL.
Majority of Clinical Trials Planned in 2018 Belong to Oncology
Cancer is one of the leading causes of morbidity and mortality across the world. Not surprisingly, oncology is going to be the top therapy areafor clinical trialsplanned to be initiated in 2018…
Evotec & Sanofi to Create an Evotec-Led Infectious Disease Open Innovation R&D Platform
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France.
BC Platforms Launches End-to-End Solution for Precision Medicine Powered by the Microsoft Genomics Service
BC Platforms, a pioneer in genomic data management and analytics, recently announced it has launchedGeneVision, a new end-to-end Solution for Precision Medicine, that uses theMicrosoft Genomics service which runs on Microsoft Azure.
Vividion Therapeutics Announces Strategic Research Collaboration With Celgene; $101 Million Up-Front Payment
Vividion Therapeutics, Inc., a biotechnology company using revolutionary proteomics and chemistry platforms,recently announced a strategic research collaboration with Celgene Corporation. The multi-year collaboration is focused…
Aduro Announces Development Milestone Achieved Under Merck Collaboration
Aduro Biotech, Inc. recently announced that the company earned a $3-million development milestone payment under its worldwide licensing agreement with Merck…
